Novaliq and Laboratoires Théa announced the European Commission’s approval of Vevizye (ciclosporin 0.1% eye drops solution) for the treatment of moderate-to-severe dry eye disease (DED) in adults unresponsive to tear substitutes. Vevizye is based on Novaliq’s proprietary EyeSol water-free technology. In conjunction with this approval, Théa has acquired the rights to commercialize Vevizye in Europe, as well as selected markets in the Middle East and North Africa (MENA).

According to the company, Vevizye is designed to provide relief by reducing inflammation and improving ocular surface health. The product was approved by the FDA in May 2023 as Vevye.